Alumis Inc. is a cutting-edge technology company specializing in the development and commercialization of innovative solutions within the healthcare sector
Focused on enhancing patient care and operational efficiencies, the company harnesses advanced data analytics and artificial intelligence to provide healthcare providers with actionable insights and tools. Their offerings aim to improve patient outcomes, streamline workflows, and reduce costs, positioning Alumis as a key player in the transformation of healthcare services. Through their commitment to research and development, the company strives to address the evolving needs of the medical community and empower healthcare professionals with the resources necessary for excellence in care delivery.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Alumis stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals.
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, to acquire all of the outstanding shares of ACELYRIN for $3.00 per share in cash, plus a contingent value right that represents the right to receive 80% of the net proceeds from any out-license or disposition of ACELYRIN’s development programs or intellectual property.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. is fair to Alumis shareholders. Upon closing of the proposed transaction, Alumis shareholders will own approximately 55% of the combined company.
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers Squibb's Sotyktu, indicating strong growth potential in the TYK2 market.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September:
